Suzetrigine for Cancer-Related Bone Pain: A Three-Patient Case Series

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Cancer-related bone pain is a significant clinical issue, especially in metastatic disease.
• Conventional therapies are often insufficient for advanced cases.
• Suzetrigine, a NaV1.8 inhibitor, is a potential non-opioid analgesic for pain states.

Purpose of the Study:

• To evaluate the efficacy of suzetrigine in patients with advanced cancer-related bone pain.
• To assess suzetrigine's utility in opioid-tolerant patients with metastatic spinal cancer.

Main Methods:

• A case series of three patients with metastatic spinal cancer experiencing bone pain.
• Patients underwent a three-week trial of suzetrigine.
• Pain improvement and adverse effects were monitored.

Main Results:

• No meaningful pain improvement was observed in any of the three patients during the trial.
• Treatment was discontinued due to lack of efficacy.
• Cost was a factor in discontinuation for one patient.
• No adverse effects were reported.

Conclusions:

• Suzetrigine demonstrated limited efficacy in this small case series of advanced cancer-related bone pain.
• Its utility may be restricted in opioid-tolerant patients.
• Further research is needed to define suzetrigine's role in cancer pain management.